Expert review of anti-infective therapy
-
Expert Rev Anti Infect Ther · Nov 2014
ReviewCeftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections.
During the mid-nineties, 95-97% of intra-abdominal infection (IAI)- associated microbes were susceptible to commonly used antibiotics. Nowadays, in Gram-negative bacilli, β-lactam resistance and the associated co-resistance to other antibiotics leading to multidrug resistance is reaching crisis proportions. ⋯ In this setting, this article reviews the place in the therapeutic armamentarium of ceftolozane/tazobactam, a new cephalosporin/β-lactamase inhibitor with good activity against extended spectrum β-lactamase producing Enterobacteriaceae, with stability to AmpC β-lactamases and good anti-pseudomonal activity being stable against the most common resistance mechanisms driven by mutation in Pseudomonas aeruginosa. A profound review of its in vitro activity, in vivo efficacy in animal models, pharmacodynamics, pharmacokinetics, clinical efficacy in clinical trials in complicated IAIs and safety data is performed.